NIFTY24,173.050.84%
SENSEX77,664.001.09%
BANKNIFTY56,305.001.43%
NIFTY IT30,124.301.22%
PHARMA22,986.352.36%
AUTO25,828.102.35%
FMCG51,140.500.11%
METAL12,786.250.82%
REALTY788.651.83%
ENERGY39,996.750.25%
NIFTY24,173.050.84%
SENSEX77,664.001.09%
BANKNIFTY56,305.001.43%
NIFTY IT30,124.301.22%
PHARMA22,986.352.36%
AUTO25,828.102.35%
FMCG51,140.500.11%
METAL12,786.250.82%
REALTY788.651.83%
ENERGY39,996.750.25%

Biocon Launches Tech-Enabled Public Transport Programme for Employees

Bengaluru, April 23: Biocon, a leading biotechnology company, has rolled out a tech-enabled programme to promote the use of public transport among its employees, in partnership with the Toyota Mobility Foundation and WRI India. As part of the programme, Biocon has deposited a one-time Rs 2,000 in the Tummoc app, which enables employees to plan, track, and pay for journeys across metro, bus, and feeder services through a single interface.

The platform integrates real-time information, ticketing, and multimodal connectivity, along with enterprise features aligned with Biocon's Environmental, Social, and Governance (ESG) requirements. Developed in consultation with Biocon's team, the solution includes features such as gamification, usage tracking, and leaderboards, as well as backend dashboards on commuting patterns, carbon dioxide savings, and user trends.

The programme has seen strong early adoption, with around 6,000 Metro tickets sold and nearly 500 employees using feeder services daily. This traction has been achieved even before financial incentives were introduced, indicating the potential for sustained behavioural change.

Read also: Indian Economy Maintains Stability Amid West Asia Conflict-Driven Energy Price and Input Cost Increases.

The Corporate Commute Nudge programme is part of the Station Access and Mobility Program (STAMP), spearheaded by the Toyota Mobility Foundation and WRI India, with support from Electronics City Industries Association, BMRCL, and BMTC. It focuses on improving first- and last-mile connectivity to make public transport a reliable choice.

Key Statistics Comparison

Programme FeatureCurrent StatusTarget
Metro tickets sold6,00010,000
Employees using feeder services daily5001,000

The programme has already shown positive results, with early findings indicating that employees using Metro are experiencing better quality of life and less stressful commutes. This has reinforced the need to improve frequency and last-mile connectivity. Biocon has also supported the development of the Biocon-Hebbagodi Metro station on the Yellow Line of Namma Metro.

Read also: FM Sitharaman Warns Bankers of Emerging AI Threats Amid Rising Concerns Over Anthropic Disruption

Impact on Congestion

The programme has led to an estimated 25-30 percent reduction in vehicles following the Yellow Line launch, according to the Bengaluru city police commissioner, Seemant Kumar Singh. Improved integration has also helped tackle congestion at its source, aligning corporate policy with city infrastructure, as stated by Maheshwar Rao, chief commissioner, Greater Bengaluru Authority (GBA).

Scalable Model

The success of the Biocon launch proves that shifting commuter behaviour is possible with data-driven technology and corporate leadership, according to Srinivas Alavilli, fellow, WRI India. The programme shows how technology and behavioural insights can make sustainable travel more intuitive, making it a scalable model for other companies to follow.

IPOScanner Logo

IPOScanner helps investors track upcoming, live and past IPOs in one place with GMP, subscription, allotment status and listing performance insights.

About IPO Scanner

IPOScanner is built for investors who want a clear view of every IPO opportunity in one place. From upcoming issues to live subscription data, allotment updates and listing performance, we bring together the key details you need to track the primary market.

Our tools are designed to be simple, fast and investor-friendly so you can focus on evaluating businesses instead of opening multiple tabs and websites for basic information.

Details of client bank account
For any query / feedback / clarifications, email at
help@iposcanner.ai.

Please read all offer documents and risk disclosures carefully before investing. IPOScanner does not provide investment advice and information on this site should not be treated as a recommendation to apply for any IPO.

© 2026 IPO Scanner. All rights reserved.